Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2 /neu or EpCAM as target receptors

Ferlay, 2013 Goldenberg, 1999, Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer, Clin Ther, 21, 309, 10.1016/S0149-2918(00)88288-0 Eroles, 2012, Molecular biology in breast cancer: intrinsic subtypes and signaling pathways, Cancer Treat Rev, 38, 698, 10.1016/j.ctrv.2011.11.005 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Meden, 1997, Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor, Eur J Obstet Gynecol Reprod Biol, 71, 173, 10.1016/S0301-2115(96)02630-9 Vu, 2014, Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer, Biochim Biophys Acta, 1846, 353 Yap, 2009, Beyond chemotherapy: targeted therapies in ovarian cancer, Nat Rev Cancer, 9, 167, 10.1038/nrc2583 Nahta, 2006, Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer, Nat Clin Pract Oncol, 3, 269, 10.1038/ncponc0509 Jordan, 2006, Cancer stem cells, N Engl J Med, 355, 1253, 10.1056/NEJMra061808 Meacham, 2013, Tumour heterogeneity and cancer cell plasticity, Nature, 501, 328, 10.1038/nature12624 Munz, 2009, The emerging role of EpCAM in cancer and stem cell signaling, Cancer Res, 69, 5627, 10.1158/0008-5472.CAN-09-0654 Visvader, 2008, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions, Nat Rev Cancer, 8, 755, 10.1038/nrc2499 Gires, 2009, On the abundance of EpCAM on cancer stem cells, Nat Rev Cancer, 9, 143, 10.1038/nrc2499-c1 Gastl, 2000, Ep-CAM overexpression in breast cancer as a predictor of survival, Lancet, 356, 1981, 10.1016/S0140-6736(00)03312-2 Spizzo, 2002, Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer, Int J Cancer, 98, 883, 10.1002/ijc.10270 Spizzo, 2004, High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer, Breast Cancer Res Treat, 86, 207, 10.1023/B:BREA.0000036787.59816.01 Spizzo, 2006, Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer, Gynecol Oncol, 103, 483, 10.1016/j.ygyno.2006.03.035 Greig, 2016, Talimogene Laherparepvec: first global approval, Drugs, 76, 147, 10.1007/s40265-015-0522-7 Russell, 2012, Oncolytic virotherapy, Nat Biotechnol, 30, 658, 10.1038/nbt.2287 Miest, 2014, New viruses for cancer therapy: meeting clinical needs, Nat Rev Microbiol, 12, 23, 10.1038/nrmicro3140 US National Institutes of Health Russell, 2014, Remission of disseminated cancer after systemic oncolytic virotherapy, Mayo Clin Proc, 89, 926, 10.1016/j.mayocp.2014.04.003 Moss, 2006, Global measles elimination, Nat Rev Microbiol, 4, 900, 10.1038/nrmicro1550 Dörig, 1993, The human CD46 molecule is a receptor for measles virus (Edmonston strain), Cell, 75, 295, 10.1016/0092-8674(93)80071-L Naniche, 1993, Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus, J Virol, 67, 6025, 10.1128/JVI.67.10.6025-6032.1993 Tatsuo, 2000, SLAM (CDw150) is a cellular receptor for measles virus, Nature, 406, 893, 10.1038/35022579 Noyce, 2011, Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus, PLoS Pathog, 7, e1002240, 10.1371/journal.ppat.1002240 Mühlebach, 2011, Adherens junction protein nectin-4 is the epithelial receptor for measles virus, Nature, 480, 530, 10.1038/nature10639 Fishelson, 2003, Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors, Mol Immunol, 40, 109, 10.1016/S0161-5890(03)00112-3 Anderson, 2004, High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus, Cancer Res, 64, 4919, 10.1158/0008-5472.CAN-04-0884 Navaratnarajah, 2011, The heads of the measles virus attachment protein move to transmit the fusion-triggering signal, Nat Struct Mol Biol, 18, 128, 10.1038/nsmb.1967 Vongpunsawad, 2004, Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model, J Virol, 78, 302, 10.1128/JVI.78.1.302-313.2004 Nakamura, 2005, Rescue and propagation of fully retargeted oncolytic measles viruses, Nat Biotechnol, 23, 209, 10.1038/nbt1060 Schneider, 2000, Recombinant measles viruses efficiently entering cells through targeted receptors, J Virol, 74, 9928, 10.1128/JVI.74.21.9928-9936.2000 Hallak, 2005, Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression, Cancer Res, 65, 5292, 10.1158/0008-5472.CAN-04-2879 Friedrich, 2013, DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety, Mol Ther, 21, 849, 10.1038/mt.2013.16 Plückthun, 2015, Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy, Annu Rev Pharmacol Toxicol, 55, 489, 10.1146/annurev-pharmtox-010611-134654 Zahnd, 2007, A designed ankyrin repeat protein evolved to picomolar affinity to Her2, J Mol Biol, 369, 1015, 10.1016/j.jmb.2007.03.028 Stefan, 2011, DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency, J Mol Biol, 413, 826, 10.1016/j.jmb.2011.09.016 Steiner, 2008, Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display, J Mol Biol, 382, 1211, 10.1016/j.jmb.2008.07.085 Calain, 1993, The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA, J Virol, 67, 4822, 10.1128/JVI.67.8.4822-4830.1993 Peng, 2002, Intraperitoneal therapy of ovarian cancer using an engineered measles virus, Cancer Res, 62, 4656 Heidmeier, 2014, A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains, Virus Res, 180, 43, 10.1016/j.virusres.2013.12.016 Winkler, 2009, EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins, Mol Cancer Ther, 8, 2674, 10.1158/1535-7163.MCT-09-0402 Binz, 2003, Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins, J Mol Biol, 332, 489, 10.1016/S0022-2836(03)00896-9 Buchholz, 1996, Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion, J Virol, 70, 3716, 10.1128/JVI.70.6.3716-3723.1996 Brindley, 2015, Measles virus glycoprotein complexes preassemble intracellularly and relax during transport to the cell surface in preparation for fusion, J Virol, 89, 1230, 10.1128/JVI.02754-14 Patel, 2011, Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights, Mol Ther, 19, 1034, 10.1038/mt.2011.44 Ayala-Breton, 2014, Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus, J Virol, 88, 8332, 10.1128/JVI.03823-13 Hasegawa, 2007, Affinity thresholds for membrane fusion triggering by viral glycoproteins, J Virol, 81, 13149, 10.1128/JVI.01415-07 Jost, 2013, Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2, Structure, 21, 1979, 10.1016/j.str.2013.08.020 Galanis, 2015, Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer, Cancer Res, 75, 22, 10.1158/0008-5472.CAN-14-2533 Hasegawa, 2006, The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer, Clin Cancer Res, 12, 6170, 10.1158/1078-0432.CCR-06-0992 Zielinski, 2011, HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors, Clin Cancer Res, 17, 5071, 10.1158/1078-0432.CCR-10-2887 Hubalek, 2010, Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment, Wien Med Wochenschr, 160, 506, 10.1007/s10354-010-0838-6 Valabrega, 2007, Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer, Ann Oncol, 18, 977, 10.1093/annonc/mdl475 Lesniak, 2013, Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer, PLoS One, 8, e71987, 10.1371/journal.pone.0071987 Manchester, 1994, Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus, Proc Natl Acad Sci USA, 91, 2161, 10.1073/pnas.91.6.2161 Fabre-Lafay, 2005, Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17, J Biol Chem, 280, 19543, 10.1074/jbc.M410943200 Münch, 2011, DARPins: an efficient targeting domain for lentiviral vectors, Mol Ther, 19, 686, 10.1038/mt.2010.298 Münch, 2015, Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors, Nat Commun, 6, 6246, 10.1038/ncomms7246 Studer, 1985, Characterization of four human malignant glioma cell lines, Acta Neuropathol, 66, 208, 10.1007/BF00688585 Funke, 2008, Targeted cell entry of lentiviral vectors, Mol Ther, 16, 1427, 10.1038/mt.2008.128 Bach, 2013, Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus, Cancer Res, 73, 865, 10.1158/0008-5472.CAN-12-2221 Ungerechts, 2007, Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine, Cancer Res, 67, 10939, 10.1158/0008-5472.CAN-07-1252 Friedel, 2015, Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv, Protein Eng Des Sel, 28, 93, 10.1093/protein/gzv005 Martin, 2006, RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication, J Virol, 80, 5708, 10.1128/JVI.02389-05 Hubert, 1984, 65 Kärber, 1931, Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche, Arch Exp Pathol Pharmakol, 480, 10.1007/BF01863914 Cathomen, 1995, Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region, Virology, 214, 628, 10.1006/viro.1995.0075 Cathomen, 1998, Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence, J Virol, 72, 1224, 10.1128/JVI.72.2.1224-1234.1998 Richardson, 1980, Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides, Virology, 105, 205, 10.1016/0042-6822(80)90168-3 Gerlier, 1995, CD46-mediated measles virus entry: a first key to host-range specificity, Trends Microbiol, 3, 338, 10.1016/S0966-842X(00)88972-6 Cattaneo, 2010, Paramyxovirus entry and targeted vectors for cancer therapy, PLoS Pathog, 6, e1000973, 10.1371/journal.ppat.1000973 Merz, 2008, Stabilizing ionic interactions in a full-consensus ankyrin repeat protein, J Mol Biol, 376, 232, 10.1016/j.jmb.2007.11.047